Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 446-452

  Watanabe, Ryohei ^e   Matsumoto, Tetsuya ^a,d   Sano, Go ^b   Ishii, Yoshikazu ^a   Tateda, Kazuhiro ^a   Sumiyama, Yoshinobu ^e   Uchiyama, Jumpei ^c   Sakurai, Shingo ^c   Matsuzaki, Shigenobu ^c   Imai, Shosuke ^c   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; BACTERIOPHAGE; BACTERIOPHAGE KPP10; BACTERIOPHAGE THERAPY; BLOOD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ELECTRON MICROSCOPY; FEMALE; GASTROINTESTINAL TRACT; LIVER; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; SEPTICEMIA; SPLEEN; SURVIVAL RATE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL THERAPY; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; LIVER; LOWER GASTROINTESTINAL TRACT; MICE; MICE, INBRED ICR; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; SEPSIS;

EID: 33846612678     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00635-06     Document Type: Article

References (43)

1. Alisky, J., K. Iczkowski, A. Rapoport, and N. Troitsky. 1998. Bacteriophages show promise as antimicrobial agents. J. Infect. 36:5-15.
2. Anonymous. 1983. Phage therapy. Lancet ii:1287-1288. (Editorial.)
3. Barrow, P., M. Lovell, and A. Berchieri, Jr. 1998. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin. Diagn. Lab. Immunol. 5:294-298.
4. Barrow, P. A., and J. S. Soothill. 1997. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 5:268-271.
5. Berg, R. D., and A. W. Garlington. 1980. Translocation of Escherichia coli from the gastrointestinal tract to the mesenteric lymph nodes in gnotobiotic mice receiving Escherichia coli vaccines before colonization. Infect. Immun. 30:894-898.
6. Biswas, B., S. Adhya, P. Washart, B. Paul, A. N. Trostel, B. Powell, R. Carlton, and C. R. Merril. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70:204-210.
7. Bodey, G. P., R. Bolivar, V. Fainstein, and L. Jadeja. 1983. Infections caused by Pseudomonas aeruginosa. Rev. Infect. Dis. 5:279-313.
8. Damas, P., D. Ledoux, M. Nys, Y. Vrindts, D. De Groote, P. Franchimont, and M. Lamy. 1992. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann. Surg. 215:356-362.
9. Deitch, E. A., J. Winterton, and R. Berg. 1986. Thermal injury promotes bacterial translocation from the gastrointestinal tract in mice with impaired T-cell-mediated immunity. Arch. Surg. 121:97-101.
10. Duckworth, D. H., and P. A. Gulig. 2002. Bacteriophages: potential treatment for bacterial infections. BioDrugs 16:57-62.
11. Elliott, R. M., and C. D. Green. 1989. A simple purification procedure for lambda gt bacteriophage DNA with hybridization size screening for isolation of longest length cDNA clones. Anal. Biochem. 183:89-93.
12. Hagens, S., A. Habel, U. von Ahsen, A. von Gabain, and U. Blasi. 2004. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 48:3817-3822.
13. Hirakata, Y., M. Kaku, K. Tomono, K. Tateda, N. Furuya, T. Matsumoto, R. Araki, and K. Yamaguchi. 1992. Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice. Antimicrob. Agents Chemother. 36:1198-1203.
14. Hirakata, Y., K. Tomono, K. Tateda, T. Matsumoto, N. Furuya, K. Shimoguchi, M. Kaku, and K. Yamaguchi. 1991. Role of bacterial association with Kupffer cells in occurrence of endogenous systemic bacteremia. Infect. Immun. 59:289-294.
15. Ho, K. 2001. Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotics era. Perspect. Biol. Med. 44:1-16.
16. Jado, I., R. Lopez, E. Garcia, A. Fenoll, J. Casal, and P. Garcia. 2003. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 52:967-973.
17. Lederberg, J. 1996. Smaller fleas ad infinitum: therapeutic bacteriophage redux. Proc. Natl. Acad. Sci. USA 93:3167-3168.
18. Lowbury, E. J., and A. M. Hood. 1953. The acquired resistance of Staphylococcus aureus to bacteriophage. J. Gen. Microbiol. 9:524-535.
19. Matsumoto, T., K. Tateda, N. Furuya, S. Miyazaki, A. Ohno, Y. Ishii, Y. Hirakata, and K. Yamaguchi. 1998. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice. J. Med. Microbiol. 47:303-308.
20. Matsumoto, T., K. Tateda, S. Miyazaki, N. Furuya, A. Ohno, Y. Ishii, Y. Hirakata, and K. Yamaguchi. 1997. Adverse effects of tumor necrosis factor in cyclophosphamide-treated mice subjected to gut-derived Pseudomonas aeruginosa sepsis. Cytokine 9:763-769.
21. Matsumoto, T., K. Tateda, S. Miyazaki, N. Furuya, A. Ohno, Y. Ishii, Y. Hirakata, and K. Yamaguchi. 1998. Effect of immunisation with Pseudomonas aeruginosa on gut-derived sepsis in mice. J. Med. Microbiol. 47:295-301.
22. Matsumoto, T., K. Tateda, S. Miyazaki, N. Furuya, A. Ohno, Y. Ishii, Y. Hirakata, and K. Yamaguchi. 1998. Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 42:2853-2857.
23. Matsumoto, T., K. Tateda, S. Miyazaki, N. Furuya, A. Ohno, Y. Ishii, Y. Hirakata, and K. Yamaguchi. 1997. Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 41:308-313.
24. Matsuzaki, S., M. Yasuda, H. Nishikawa, M. Kuroda, T. Ujihara, T. Shuin, Y. Shen, Z. Jin, S. Fujimoto, M. D. Nasimuzzaman, H. Wakiguchi, S. Sugihara, T. Sugiura, S. Koda, A. Muraoka, and S. Imai. 2003. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J. Infect. Dis. 187:613-624.
25. Matsuzaki, S., M. Rashel, J. Uchiyama, S. Sakurai, T. Ujihara, M. Kuroda, M. Ikeuchi, T. Tani, M. Fujieda, H. Wakiguchi, and S. Imai. 2005. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J. Infect. Chemother. 11:211-219.
26. Matthay, M. A. 2001. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. N. Engl. J. Med. 344:759-762.
27. Merril, C. R., B. Biswas, R. Carlton, N. C. Jensen, G. J. Creed, S. Zullo, and S. Adhya. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA 93:3188-3192.
28. Pirisi, A. 2000. Phage therapy - advantages over antibiotics? Lancet 356:1418.
29. Pruitt, B. A., Jr., A. T. McManus, S. H. Kim, and C. W. Goodwin. 1998. Burn wound infections: current status. World J. Surg. 22:135-145.
30. Puren, A. J., C. Feldman, N. Savage, P. J. Becker, and C. Smith. 1995. Patterns of cytokine expression in community-acquired pneumonia. Chest 107:1342-1349.
31. Rosenfeld, M., B. W. Ramsey, and R. L. Gibson. 2003. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr. Opin. PuIm. Med. 9:492-497.
32. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, vol. 1, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
33. Slopek, S., B. Weber-Dabrowska, M. Dabrowski, and A. Kucharewicz-Krukowska. 1987. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. (Warsaw) 35:569-583.
34. Smith, H. W., and M. B. Huggins. 1983. Effectiveness of phages in treating experimental Escherichia coli diarrhea in calves, piglets and lambs. J. Gen. Microbiol. 129:2659-2675.
35. Smith, H. W., and M. B. Huggins. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318.
36. Smith, H. W., M. B. Huggins, and K. M. Shaw. 1987. The control of experimental Escherichia coli diarrhea in calves by means of bacteriophages. J. Gen. Microbiol. 133:1111-1126.
37. Soothill, J. S. 1992. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. 37:258-261.
38. Soothill, J. S. 1994. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 20:209-211.
39. Speert, D. P., M. E. Campbell, D. A. Henry, R. Milner, F. Taha, A. Gravelle, A. G. Davidson, L. T. Wong, and E. Mahenthiralingam. 2002. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am. J. Respir. Crit. Care Med. 166:988-993.
40. Steinstraesser, L., Y. Oezdogan, S. C. Wang, and H. U. Steinau. 2004. Host defense peptides in burns. Burns 30:619-627.
41. Sulakvelidze, A., Z. Alavidze, and J. G. Morris, Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 45:649-659.
42. Tancrede, C. H., and A. O. Andremont. 1985. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J. Infect. Dis. 152:99-103.
43. Weber-Dabrowska, B., M. Mulczyk, and A. Gorski. 2000. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch. Immunol. Ther. Exp. (Warsaw) 48:547-551.